CardiaCare Raises Seed Funding for Cardiac Clinical Studies

Rehovot, Israel, September 18, 2026

CardiaCare Expands Clinical Development Program

The newly raised capital is intended to support existing and future clinical studies evaluating CardiaCare’s technology. According to the company, the platform is being developed to provide non-invasive neuromodulation treatment for patients with cardiac arrhythmias, with atrial fibrillation representing a major focus of the clinical program. CardiaCare said the funding will help expand studies designed to generate clinical evidence on the efficacy of its therapeutic approach. The company’s technology is based on drug-free neuromodulation, offering a non-invasive approach to cardiac rhythm management.

CardiaCare is developing the platform as a wearable system that can deliver neuromodulation stimulation while also collecting information that may help physicians remotely monitor patients. The company said the platform is designed to use real-time patient-condition data to support dynamic and personalized treatment. The financing was led by Solardis Health Ventures, with the company describing the round as oversubscribed. CardiaCare said the participation of investors with clinical and commercial experience would support its efforts to advance the technology through clinical development and toward potential commercialization.

Wearable Neuromodulation Targets Cardiac Arrhythmias

CardiaCare’s platform is being developed around the concept of using neuromodulation to influence cardiac rhythm without relying on pharmaceutical therapy or invasive procedures. The company is targeting atrial fibrillation, one of the most common cardiac arrhythmias, as well as other potential indications associated with abnormal heart rhythms. The wearable approach is intended to provide treatment outside conventional hospital-based procedures while allowing healthcare professionals to monitor patients remotely. CardiaCare’s platform combines therapeutic stimulation and patient monitoring, creating an integrated approach to managing cardiac arrhythmias. The company said its longer-term objective is to develop an all-in-one therapeutic monitoring platform that can support patients across the continuum of cardiac care. CardiaCare said multiple clinical studies were already underway when the financing was announced. The company plans to use the additional funding to support further multicenter clinical research designed to evaluate the efficacy of its neuromodulation therapy across different cardiac arrhythmia indications.

Seed Funding Supports MedTech Innovation

The completion of the Seed Extension round provides CardiaCare with additional resources to advance its clinical-stage medical device technology. Funding is particularly important for medical-device companies developing novel therapeutic platforms because clinical validation requires carefully designed studies, specialized clinical sites and long-term patient follow-up. The company said its clinical program will include double-blind and multicenter studies, approaches that can provide more robust evidence regarding the performance of an investigational therapy. Future clinical findings will be important in determining whether CardiaCare’s wearable neuromodulation technology can demonstrate meaningful benefits for patients with atrial fibrillation and other arrhythmias.

CardiaCare’s development strategy reflects a broader trend toward wearable medical devices, remote monitoring and non-invasive therapeutic technologies in cardiovascular care. Advances in digital health and neuromodulation are creating opportunities to combine continuous patient data with personalized treatment approaches, potentially allowing therapies to be delivered outside traditional clinical settings. For CardiaCare, the Seed Extension financing represents a step toward advancing its wearable platform through clinical development. The company will use the funding to support ongoing and future clinical research while continuing development of its drug-free neuromodulation technology for cardiac arrhythmias. As additional clinical data become available, the studies will help characterize the safety and efficacy of the platform and inform its future development and regulatory strategy.

Source: CardiaCare, StimCardio press release